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LETTER TO THE EDITOR

Aspirin in Primary Prevention of
Myocardial Infarction/Angina and
Stroke in Hypertensive Patients

Sir,

Hypertension is the leading attributable risk factor for
mortality in the global burden of cardiovascular diseases
(CVD).1 Role of aspirin has been under debate in the
past decade. In contrast, in a recent systematic review
published in 2015 on 103,787 patients, reported risk of
major gastrointestinal bleeding was increased and risk
of hemorrhagic stroke or other intracranial bleeding
tended to be increased in primary prevention trials in
patients on aspirin.2

In many large trials which were conducted, the use of
aspirin and cardiovascular outcomes on South-Asian
population was not represented although they are
relatively at higher risk of CVD.3 Hence, aspirin use for
prevention of CVD may have different results (both
beneficial and adverse outcomes). So, the objective of
this study is to determine the impact of aspirin use on
cardiovascular disease including myocardial infarction
(MI/angina and stroke) in hypertensive patients.

We did a cross-sectional study conducted in the
Department of Medicine, The Aga Khan University
Hospital, Karachi, Pakistan over a 3-year period from
2010 to 2012. Ethical clearance was taken from the
Ethics Review Committee of The Aga Khan University
(2827-Med-ERC-13). All participants aged greater than
40 years with history of hypertension, admitted through
emergency room with MI/angina or stroke, were
recruited. History of using aspirin was recorded.
Hypertension was defined as SBP >140 mm Hg and
DBP >90 mm Hg.4 Use of aspirin defined as using a
minimum dose of 75-81 mg of aspirin for minimum 4
weeks prior to ER visit was recorded.
A total of 575 patients were included in the study. Mean
age was 63.96 +11.67 years, of which 372 (64.7%) were
males and 203 (35%) were females. Aspirin use was
present in 330 (57.4%) patients. Out of the 343 (59.7%)
who had MI/angina, 208/343 (60.6%) were on aspirin for
upto one month prior to the ER visit. Out of the 193
(33.6%) stroke patients, 99/193 (51.3%) were on aspirin.
Upper gastrointestinal bleeding occurred in 49 (8%)
patients and 26 (4.5%) were on aspirin. The OR of use

of aspirin with myocardial infarction/angina and stroke is
reported in Table I.
Use of aspirin did not show a clear benefit in primary
prevention for ischemic heart diseases (IHD) and stroke
in this hypertensive patient population. This concept has
remained a topic of debate in the last decade. As use of
aspirin in secondary prevention of IHD and stroke is well
established in the high-risk prevalent atherosclerotic
cardiovascular diseases including IHD and stroke,
aspirin decreases acute CVD event (approximately 20%
reduction in coronary events and total stroke).5 This study
demonstrated that there is no clear role of aspirin in
primary prevention of IHD or stroke in hypertensive
patients. Hence, we conclude that aspirin has no clear
role in primary prevention of IHD or stroke in hypertensive
patients; and this effect is irrespective of age and gender.
However, more studies are required to further confirm
this conclusion as this study has limited external validity.
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Table I: Association of aspirin use with ischemic heart disease and stroke adjusted for covariates.
Aspirin used N (%)
208 (60.6)
99 (51.3)

Crude OR 95% CI

p-value

0.76 (0.5,1.0)

0.06

0.69 (0.49,0.9)

0.04

Adjusted model *

p-value

Adjusted Model**

p-value

0.72 (0.5,1.0)

0.06

0.8 (0.51,1.2)

0.3

0.7 (0.49,1.0)

0.7

0.7 (0.5,1.1)

0.2

OR 95% CI

Ischemic heart disease (N=343)
Stroke (N=193)

*Adjusted for age and gender **Adjusted for prior history of myocardial infarction, stroke, diabetes , dyslipidemia and chronic kidney disease.

574

OR 95% CI
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